Future Science Group

sorry, we can't preview this file

...but you can still download supplementary figures.pptm
supplementary figures.pptm (136.61 kB)

Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum: Supplementary figures

Download (136.61 kB)
posted on 2022-11-15, 18:16 authored by Oladipo S Idowu, Jenny L Craigen, Gareth J Veal, David Jamieson

Background: HMBD-001 is an IgG1 humanized monoclonal antibody specifically targeting HER3, a receptor

highly expressed on cancer cells in certain tumors. A bioanalytical method was required to quantify HMBD-

001 in human serum, with high selectivity and without interference from HER3. Methods and results: A

bridging ELISA using an anti-idiotypic monoclonal capture and detection was developed and validated

for quantitative measurement of HMBD-001 in human serum. The assay is sensitive, with a lower limit

of quantification of 250 ng/ml, has a broad dynamic range of 250–7000 ng/ml HMBD-001, and exhibits

excellent precision and overall accuracy. Conclusion: We have developed and validated a sensitive and

selective method for measuring HMBD-001 in human serum. This assay is now being used in a clinical trial



The work was undertaken under the sponsorship and management of Cancer Research UK Centre for Drug Development and Cancer Research UK Centre Award (no. CTRQQR-2021\100003).


Usage metrics